Alps Advisors Inc Immunic, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.13 - $12.25 $89,759 - $351,293	-28,677 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $16,151 - $24,142	-1,693 Reduced 5.57%	28,677 $324,000
Q4 2021 Feb 09, 2022	SELL	$7.34 - $10.25 $13,189 - $18,419	-1,797 Reduced 5.59%	30,370 $291,000
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $28,384 - $46,860	3,526 Added 12.31%	32,167 $285,000
Q2 2021 Aug 11, 2021	SELL	$11.76 - $16.85 $113,566 - $162,720	-9,657 Reduced 25.22%	28,641 $351,000
Q1 2021 May 07, 2021	BUY	$14.21 - $25.3 $12,064 - $21,479	849 Added 2.27%	38,298 $610,000
Q4 2020 Feb 03, 2021	BUY	$14.8 - $20.37 $554,245 - $762,836	37,449 New	37,449 $573,000

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33.9M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.